M.S. Dmitrenko ¹, K.К. Smagulova ^1,2, R.Z. Abdrahmanov ^1,2, R.K. Raskaliev ¹, I.T. Turkpenova ¹, E.P. Medetbekova ¹, S.N. Kaldarbekov ¹, A.O. Kuanysh ¹, Z.S. Kenzhebayeva ¹, D.U. Shayakhmetova ², A.Zh. Zhiyenbayeva ¹, A.K. Dzhakipbaeva ²

1. Kazakh Institute of Oncology and Radiology JSC, Almaty, the Republic of Kazakhstan;
2. Asfendiyarov Kazakh National Medical University NCJSC, Almaty, the Republic of Kazakhstan

DOI: https://www.doi.org/10.52532/2521-6414-2022-4-66-64-68

UDC: 616.33-006.6:615.37

Year: 2022 issure: 66 number: 4 pages: 64-68

Download PDF:

ABSTRACT

Relevance: Gastric cancer is one of the most common malignant neoplasms and ranks fifth in cancer incidence worldwide. The only curative approach to localized gastric cancer is radical surgery with or without prior chemotherapy. But chemotherapy is the main treatment method for metastatic or locally advanced gastric cancer. Later stages of gastric cancer are highly resistant to chemotherapy; therefore, there is a need for modern treatment approaches. Particular attention is paid to therapy for metastatic/locally advanced gastric cancer.

The study aimed to describe the possibilities of using immune checkpoint inhibitors (ICIs) to treat metastatic or locally advanced gastric cancer.

Methods: The data from modern literary sources of recent years were studied using specialized scientific search engines: Scopus, PubMed, Google Scholar, and Web of Science for the possibility of promising application of various immunotherapeutic approaches in treating metastatic or locally advanced gastric cancer.

Results: The article describes modern methods of treatment of metastatic or locally advanced SC using ICIs, including PD-1, PD-L1, and CTLA-4, demonstrates the mechanisms of immunological surveillance, characteristics of PD-1, PD-L1, CTLA-4, and their significance in suppressing the T-cell response. The effectiveness of using ICIs, particularly PD-1, PD-L1, and CTLA-4, has been established in the first and subsequent lines of therapy.

Conclusion: ICIs are a recent finding in antitumor therapy. Frequent resistance of gastric cancer to chemotherapy urges the use of ICIs to treat advanced gastric cancer.

Keywords: Immunotherapy of metastatic or locally advanced gastric cancer, immune checkpoint inhibitors (ICIs), PD-1, PD-L1, CTLA-4, immune response mechanisms.

List of sources used:

1. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность) / под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. – М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. – 250 с. [Zlokachestvennye novoobrazovaniya v Rossii v 2017 godu (zabolevaemost’ i smertnost’) / pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoj. – M.: MNIOI im. P.A. Gercena – filial FGBU «NMIC radiologii» Minzdrava Rossii, 2018. – 250 s.] https://glavonco.ru/upload/pages/cancer-register/statistika_zabol_2017.pdf
2. Charalampakis N., P. Economopoulou, Kotsantis I., Tolia M., Schizas D., Liakakos T., Elimova E., Ajani J.A., Psyrri A. Medical management of gastric cancer: a 2017 update // Cancer Med. – 2018. – Vol. 7(1). – Р.123-133. https://onlinelibrary.wiley.com/doi/10.1002/cam4.1274
3. Massari F., Santoni M., Ciccarese C. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises // Cancer Treat Rev. – 2015. – Vol.41(2). – Р.114-121. https://doi.org/10.1016/j.ctrv.2014.12.013
4. Bonotto М., Garattini S.K., Basile D., Ongaro E., Fanotto V., Cattaneo M., Cortiula F., Iacono D., Cardellino G.G., Pella N., Fasola G., Antonuzzo L., Silvestris N., Aprile G. Immunotherapy for gastric cancers:emerging role and future perspectives // Expert Rev. Clin. Pharmacol. – 2017. – Vol.10 (6). – Р.609-619. https://doi.org/10.1080/17512433.2017.1313113
5. Alsina M., Moehler M., Hierro C., Guardeno R., Tabernero J. Immunotherapy for gastric Cancer: a focus on immune checkpoints // Target. Oncol. – 2016. – Vol.11. – Р.469-477. https://doi.org/10.1007/s11523-016-0421-1
6. Yang H., Wang L., Zhang J. Leukocyte modulation by natural products from herbal medicines and potential as cancer immunotherapy // J. Leukoc. Biol. – 2022. – Vol. 112. – P.185-200. https://doi.org/10.1002/JLB.3RU02 22-087
7. Motallebnezhad M., Younesi V., Aghebati-Maleki L., Nickho H., Safarzadeh E., Ahmadi M., Movassaghpour A.A., Hosseini A., Yousefi M. Antiproliferative and apoptotic effects of a specific anti-insulin-like growth factor I receptor single chain antibody on breast cancer cells // Tumour Biol. – 2016. – Vol. 37. – Р.14841-14850. https://doi.org/10.1007/s13277-016-5323-4
8. Gellrich F.F., Schmitz M., Beissert S., Meier F. Anti-PD-1 and Novel Combinations in the Treatment of Melanoma – An Update // J. Clin. Med. –2020. – Vol. 9 (1). – P. 223. https://doi.org/10.3390/jcm9010223
9. Ratner D., Lennerz J.K. Implementing Keytruda/Pembrolizumab Testing in Clinical Practice // Oncologist. – 2018. – Vol. 23 (6). – P. 647-649. https://doi.org/10.1634/theoncologist.2017-0591
10. Riley R.S., June C.H., Langer R., Mitchell M.J. Delivery technologies for cancer immunotherapy // Nat. Rev. Drug Discov. – 2019. – Vol. 18(3). – P. 175-196. https://doi.org/10.1038/s41573-018-0006-z
11. Kang Y.K., Boku N., Satoh T., Ryu M.H., Chao Y., Kato K., Chung H.C., Chen J.S., Muro K., Kang W.K. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial// Lancet – 2017. – Vol. (390). – P. 2461–2471. https://doi.org/.10.1016/S0140-6736(17)31827-5
12. Gellrich F.F., Schmitz M., Beissert S., Meier F. Anti-PD-1 and Novel Combinations in the Treatment of Melanoma – An Update // J. Clin. Med. –2020. – Vol. 9 (1). – P. 223. https://doi.org/10.3390/jcm9010223
13. Bang Y.J., Ruiz E.Y., Van Cutsem E., Lee K.W., Wyrwicz L., Schenker M., Alsina M., Ryu M. H., Chung H.C., Evesque L. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: Primary analysis of JAVELIN gastric 300 // Ann. Oncol. 2018. Vol. 29. – P. 2052–2060. https://doi.org/.10.1093/annonc/mdy264
14. Shitara К., Özgüroğlu М., Bang Y.J. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, openlabel, controlled, phase 3 trial // Lancet. – 2018. – Vol. 392 (10142). – Р.123-133. https://doi.org/.10.1016/S0140-6736(18)31257-1
15. Muro К., Chung H.C., Shankaran V. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial // Lancet Oncol. – 2016. – Vol.17 (6). – Р. 717-726. https://doi.org/.1016/S1470-2045(16)00175-3
16. Xu J.,Jiang H., Pan Y., Gu K., Cang S., Han, L., Shu Y., Li J., Zhao J., Pan H.. LBA53 – Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study//Oncology pro.Educational Portalfor Oncologists. – 2021. – Vol. 32. – P. 1331. https://doi.org/10.1016/j.annonc.2021.08.2134 .
17. Janjigian Y.Y., Bendell, J.C., Calvo E., Kim J.W., Ascierto P.A., Sharma P., Ott P.A., Bono P., Jaeger D., Evans T.J. CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). J. //Clin. Oncol. – 2016. – Vol. 34 – P. 4010. https://doi.org/10.1200/JCO.2017.76.6212
18. Taieb J., Moehler М., Boku N. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: current status and future perspectives // Cancer Treat Rev. – 2018. – Vol. 66. – Р. 104-113. https://doi.org/.10.1016/j.ctrv.2018.04.004